Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data

References

• Martinon-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 Suppl):S12–S20.
   PubMed Web of Science ®Google Scholar
• Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9(3):285–298.
   PubMed Web of Science ®Google Scholar
• Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis. 2014;14(9):813–819.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129(6):1327–1348.
   PubMed Web of Science ®Google Scholar
• Soriano-Gabarró M, Wolter J, Hogea C, et al. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region. Expert Rev Anti Infect Ther. 2011;9(9):761–774.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–861.
   PubMed Web of Science ®Google Scholar
• Peterson ME, Mile R, Li Y, et al. Meningococcal carriage in high-risk settings: a systematic review. Int J Infect Dis. 2018;73:109–117.
   PubMed Web of Science ®Google Scholar
• MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12(6):950–957.
   PubMed Web of Science ®Google Scholar
• Mbaeyi SA, Blain A, Whaley MJ, et al. Epidemiology of meningococcal disease outbreaks in the United States, 2009–2013. Clin Infect Dis. 2018 Jun 30. DOI:10.1093/cid/ciy548
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Pollard AJ. Can we control all-cause meningococcal disease in Europe? Clin Microbiol Infect. 2016;22 Suppl 5:S103–S12.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Invasive meningococcal disease. In: ECDC, editor. Annual epidemiological report for 2015. Stockholm: ECDC; 2017.
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report; 2016 [cited 2018 May 7]. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf
   Google Scholar
• Serruto D, Bottomley MJ, Ram S, et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30 Suppl 2:B87–B97.
   Web of Science ®Google Scholar
• Seib KL, Scarselli M, Comanducci M, et al. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. Expert Rev Vaccines. 2015;14:1–19.
   PubMed Web of Science ®Google Scholar
• MenB and Rotavirus Vaccines - Ireland’s Health Service. [cited 2017 Aug 30]. Available from: http://www.hse.ie/eng/health/immunisation/news/menbrotavacc.html
   Google Scholar
• Signorelli C, Chiesa V, Odone A. Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives. J Prev Med Hyg. 2015;56(3):E125–E132.
   PubMedGoogle Scholar
• Ladhani SN, Campbell H, Parikh SR, et al. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme–new challenges for public health. J Infect. 2015;71(6):611–614.
   PubMed Web of Science ®Google Scholar
• WHO vaccine-preventable diseases: monitoring system. 2018 global summary [cited 2019 Jan 23]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules?sc%5Bc%5D%5B%5D=ANDš5Bd%5D=š5Bv%5D%5B%5D=MENBš5BOK%5D=OK
   Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–2782.
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Lefebvre B, et al. Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada. Clin Infect Dis. 2017;64(9):1263–1267.
   PubMed Web of Science ®Google Scholar
• Law DK, Lorange M, Ringuette L, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17: P1.19). J Clin Microbiol. 2006;44(8):2743–2749.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135(5):798–804.
   PubMed Web of Science ®Google Scholar
• Patel M, Briere E, Duffy J, et al., Use of a novel serogroup B meningococcal vaccine in response to two university outbreaks in the US [Abstract O22]. IPNC. 2014 [cited 2017 Oct 2]. Available from: http://neisseria.org/ipnc/2014/IPNC_2014_abstracts.pdf
   Google Scholar
• Biswas HH, Han GS, Wendorf K, et al. Notes from the field: outbreak of serogroup B meningococcal disease at a university — California. MMWR Morb Mortal Wkly Rep. 2016;65(20):520–521.
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–4974.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–1176.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(RR–2):1–28.
   PubMedGoogle Scholar
• Read RC, Dull P, Bai X, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine. 2017;35(3):427–434.
   PubMed Web of Science ®Google Scholar
• Szenborn L, Block SL, Jackowska T, et al. Immune responses to booster vaccination with meningococcal ABCWY vaccine after primary vaccination with either investigational or licensed vaccines: a phase 2 randomized study. Pediatr Infect Dis J. 2018;37(5):475–482.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan M, Valenzuela MT, et al. Persistence of antibodies in adolescents 18–24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013;9(11):2304–2310.
   PubMed Web of Science ®Google Scholar
• Nolan T, Garfield H, Gupta A, et al. Persistence of bactericidal activity at 4 years after 2 primary doses of a recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) and response to a booster dose in adolescents and young adults. IDWeek. Open Forum Infect Dis. 2017;4(Suppl1):S322.
   Google Scholar
• Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial. Vaccine. 2015;33(21):2500–2510.
   PubMed Web of Science ®Google Scholar
• Perrett KP, McVernon J, Richmond PC, et al. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015;33(39):5217–5224.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617–624.
   PubMed Web of Science ®Google Scholar
• Nolan T, Santolaya M, De Looze F, et al. Antibody persistence and booster response in adolascents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019;37:1209–1218.
   Web of Science ®Google Scholar
• NCT01992536. Phase 2, observer-blind, placebo-controlled, randomized, multi-center extension study to evaluate the safety and immunogenicity of a booster dose of a menabcwy vaccine administered 24 months following the primary series to adolescents and young adults who participated in V102_03. [cited 2018 Sep 14]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01992536?cond=v102_03&rank=1&sect=Xa0156&view=results#outcome4
   Google Scholar
• Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3–B12.
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–2636.
   PubMed Web of Science ®Google Scholar
• Giuliani M, Bartolini E, Galli B, et al. Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. Sci Rep. 2018;8(1):3700.
   PubMed Web of Science ®Google Scholar
• Vu DM, Wong TT, Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine. 2011;29(10):1968–1973.
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha M-K, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416–425.
   PubMed Web of Science ®Google Scholar
• Rajam G, Stella M, Kim E, et al. Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States. mSphere. 2017;2(6):e00261–e00217.
   PubMed Web of Science ®Google Scholar
• Hong E, Giuliani MM, Deghmane A-E, et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine. 2013;31(7):1113–1116.
   PubMed Web of Science ®Google Scholar
• Abad R, Biolchi A, Moschioni M, et al. A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by Sera from adolescents and infants immunized with 4CMenB. Clin Vaccine Immunol. 2015;22(4):357–360.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Giuliani MM, Biolchi A, et al. Effectiveness of meningococcal B vaccine against endemic hypervirulent Neisseria meningitidis W Strain, England. Emerg Infect Dis. 2016;22(2):309–311.
   PubMed Web of Science ®Google Scholar
• Tomei S, Biolchi A, Brunelli B, et al. Potential coverage of the BEXSERO® MenB vaccine on non-B meningococci [Abstract P30]. XIXth International Pathogenic Neisseria Conference (IPNC); 2014 Oct 12–17. Asheville (NC): Publisher.
   Google Scholar
• Longtin J, Dion R, Simard M, et al. Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhoea incidence rates in one region of Quebec, Canada. Abstract ID Week. 2017 Oct 4–8. SanDiego.
   Google Scholar
• Arnold R, Galloway Y, McNicholas A, et al. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine. 2011;29(40):7100–7106.
   PubMed Web of Science ®Google Scholar